CTI was founded in 1999 by a small group of innovative thinkers who wanted to change the lives of chronically and critically ill patients.
In our 20 year history, CTI has grown consistently and significantly, becoming a multi-national organization with associates in more than 35 countries across the world. We have worked on more than 5000 projects, worked on every continent except Antarctica, and have contributed to more than 100 new drug and device approvals through global regulatory agencies such as the FDA, EMA, and others. Currently, we work with approximately 200 pharmaceutical and emerging biotechnology and medical device companies.
Staying true to our roots, we focus on chronically and critically ill patient populations. This focus, an active leadership team, careful hiring practices, a robust internal training program, and a consistent annual retention rate of 95% have all combined to enable the development of an expert workforce whose deep knowledge and experience differentiates our team from those of other service providers.
We have had the opportunity to witness and be a part of some major breakthroughs in the fields in which we focus, from some of the earliest developments in immunosuppression to new discoveries in regenerative medicine and cell therapies. We believe cures for debilitating diseases and prevention of catastrophic illnesses are possible in the next 10 to 15 years with advances in fields such as regenerative medicine and personalized therapies, and we are privileged to be in a leadership role for these exciting and life-changing projects.